Concepts (281)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Neoplasms | 33 | 2023 | 106 | 7.690 |
Why?
|
| Sarcoma | 15 | 2023 | 133 | 2.700 |
Why?
|
| Bone Substitutes | 9 | 2017 | 26 | 2.190 |
Why?
|
| Soft Tissue Neoplasms | 7 | 2022 | 51 | 1.850 |
Why?
|
| Bone Transplantation | 8 | 2017 | 227 | 1.700 |
Why?
|
| Giant Cell Tumor of Bone | 5 | 2022 | 11 | 1.670 |
Why?
|
| Sarcoma, Ewing | 3 | 2020 | 6 | 1.490 |
Why?
|
| Calcium Sulfate | 6 | 2012 | 20 | 1.120 |
Why?
|
| Musculoskeletal Diseases | 2 | 2015 | 41 | 0.970 |
Why?
|
| Limb Salvage | 5 | 2023 | 8 | 0.940 |
Why?
|
| Humans | 61 | 2023 | 29814 | 0.870 |
Why?
|
| Retrospective Studies | 27 | 2023 | 3325 | 0.860 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2023 | 200 | 0.850 |
Why?
|
| Hip Joint | 2 | 2016 | 357 | 0.800 |
Why?
|
| Young Adult | 13 | 2021 | 1966 | 0.750 |
Why?
|
| Leiomyosarcoma | 1 | 2021 | 20 | 0.750 |
Why?
|
| Adolescent | 16 | 2021 | 2332 | 0.740 |
Why?
|
| Adult | 24 | 2022 | 8741 | 0.740 |
Why?
|
| Osteosarcoma | 8 | 2021 | 33 | 0.730 |
Why?
|
| Child | 13 | 2021 | 1377 | 0.710 |
Why?
|
| Calcium Phosphates | 2 | 2012 | 27 | 0.710 |
Why?
|
| Fractures, Bone | 2 | 2012 | 75 | 0.670 |
Why?
|
| Child, Preschool | 9 | 2021 | 654 | 0.670 |
Why?
|
| Bone Cysts | 2 | 2016 | 2 | 0.660 |
Why?
|
| Synovitis, Pigmented Villonodular | 2 | 2016 | 2 | 0.660 |
Why?
|
| Tibia | 2 | 2010 | 266 | 0.630 |
Why?
|
| Treatment Outcome | 16 | 2023 | 3561 | 0.590 |
Why?
|
| Male | 26 | 2021 | 15851 | 0.570 |
Why?
|
| Chondromatosis, Synovial | 1 | 2016 | 4 | 0.560 |
Why?
|
| Bone Diseases | 2 | 2017 | 24 | 0.550 |
Why?
|
| Middle Aged | 21 | 2021 | 9960 | 0.550 |
Why?
|
| Arthrodesis | 2 | 2014 | 40 | 0.540 |
Why?
|
| Internal Fixators | 1 | 2016 | 52 | 0.540 |
Why?
|
| Foot | 1 | 2016 | 31 | 0.540 |
Why?
|
| Acetabulum | 3 | 2016 | 198 | 0.540 |
Why?
|
| Foreign Bodies | 1 | 2016 | 24 | 0.530 |
Why?
|
| Arthroplasty, Replacement, Knee | 5 | 2022 | 696 | 0.530 |
Why?
|
| Radiotherapy | 1 | 2016 | 53 | 0.530 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2016 | 42 | 0.530 |
Why?
|
| Female | 23 | 2021 | 16412 | 0.520 |
Why?
|
| Ultrasonography, Interventional | 1 | 2016 | 63 | 0.520 |
Why?
|
| Radius | 2 | 2014 | 32 | 0.500 |
Why?
|
| Tobramycin | 2 | 2005 | 10 | 0.470 |
Why?
|
| Knee Prosthesis | 2 | 2008 | 244 | 0.450 |
Why?
|
| Survival Rate | 5 | 2021 | 376 | 0.450 |
Why?
|
| Biopsy | 6 | 2023 | 239 | 0.430 |
Why?
|
| Arthralgia | 2 | 2011 | 122 | 0.420 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2010 | 36 | 0.410 |
Why?
|
| Anti-Bacterial Agents | 3 | 2022 | 401 | 0.410 |
Why?
|
| Chondrosarcoma | 4 | 2023 | 33 | 0.400 |
Why?
|
| Combined Modality Therapy | 3 | 2021 | 379 | 0.390 |
Why?
|
| Prognosis | 8 | 2023 | 874 | 0.390 |
Why?
|
| Histiocytosis, Sinus | 1 | 2011 | 3 | 0.380 |
Why?
|
| Talus | 1 | 2011 | 11 | 0.380 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2017 | 55 | 0.380 |
Why?
|
| Allografts | 4 | 2021 | 180 | 0.380 |
Why?
|
| Edema | 1 | 2011 | 39 | 0.370 |
Why?
|
| Follow-Up Studies | 8 | 2022 | 1859 | 0.370 |
Why?
|
| Patellar Ligament | 1 | 2010 | 52 | 0.360 |
Why?
|
| Humerus | 3 | 2005 | 101 | 0.350 |
Why?
|
| Lung Neoplasms | 2 | 2015 | 636 | 0.330 |
Why?
|
| Prosthesis Failure | 4 | 2022 | 530 | 0.330 |
Why?
|
| Osteomyelitis | 3 | 2005 | 23 | 0.330 |
Why?
|
| Debridement | 3 | 2016 | 102 | 0.320 |
Why?
|
| Femur | 4 | 2022 | 393 | 0.320 |
Why?
|
| Bone Plates | 1 | 2008 | 55 | 0.300 |
Why?
|
| Reoperation | 6 | 2022 | 927 | 0.300 |
Why?
|
| Neoadjuvant Therapy | 5 | 2022 | 63 | 0.290 |
Why?
|
| Cisplatin | 3 | 2017 | 92 | 0.280 |
Why?
|
| Osteogenesis | 1 | 2007 | 103 | 0.280 |
Why?
|
| Aged | 12 | 2021 | 9620 | 0.270 |
Why?
|
| Arthroplasty, Replacement, Hip | 3 | 2022 | 857 | 0.250 |
Why?
|
| Curettage | 3 | 2022 | 5 | 0.250 |
Why?
|
| Orthopedic Procedures | 3 | 2004 | 322 | 0.250 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2017 | 77 | 0.250 |
Why?
|
| Disease-Free Survival | 3 | 2021 | 191 | 0.250 |
Why?
|
| Aged, 80 and over | 6 | 2021 | 4930 | 0.240 |
Why?
|
| Immunohistochemistry | 4 | 2011 | 411 | 0.240 |
Why?
|
| Margins of Excision | 2 | 2022 | 21 | 0.240 |
Why?
|
| Transplantation, Homologous | 2 | 2004 | 279 | 0.240 |
Why?
|
| Infant | 3 | 2021 | 542 | 0.240 |
Why?
|
| Joint Instability | 1 | 2008 | 389 | 0.230 |
Why?
|
| Lymphatic Metastasis | 2 | 2021 | 87 | 0.230 |
Why?
|
| Pelvic Bones | 1 | 2004 | 20 | 0.230 |
Why?
|
| Embolization, Therapeutic | 1 | 2023 | 27 | 0.220 |
Why?
|
| Spinal Neoplasms | 1 | 2023 | 36 | 0.220 |
Why?
|
| Knee Joint | 2 | 2008 | 800 | 0.220 |
Why?
|
| Kidney Neoplasms | 1 | 2023 | 61 | 0.220 |
Why?
|
| Neoplasm Staging | 3 | 2022 | 364 | 0.210 |
Why?
|
| Injections | 2 | 2016 | 59 | 0.210 |
Why?
|
| Prostheses and Implants | 2 | 2015 | 165 | 0.210 |
Why?
|
| Plasma Gases | 1 | 2022 | 1 | 0.210 |
Why?
|
| Neutrophils | 1 | 2023 | 118 | 0.210 |
Why?
|
| Absorbable Implants | 1 | 2002 | 24 | 0.210 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2015 | 778 | 0.200 |
Why?
|
| Sarcoma, Synovial | 1 | 2022 | 9 | 0.200 |
Why?
|
| Infant, Newborn | 2 | 2021 | 618 | 0.200 |
Why?
|
| Vancomycin | 1 | 2002 | 58 | 0.200 |
Why?
|
| Bone Cements | 3 | 2022 | 90 | 0.200 |
Why?
|
| Apoptosis | 5 | 2022 | 259 | 0.200 |
Why?
|
| Radiography | 5 | 2015 | 678 | 0.190 |
Why?
|
| Lymphatic Vessels | 1 | 2021 | 6 | 0.190 |
Why?
|
| Myxosarcoma | 1 | 2020 | 2 | 0.190 |
Why?
|
| Fibrosarcoma | 1 | 2020 | 8 | 0.190 |
Why?
|
| Hemipelvectomy | 1 | 2020 | 1 | 0.180 |
Why?
|
| Pelvic Neoplasms | 1 | 2020 | 4 | 0.180 |
Why?
|
| Orthopedics | 1 | 2002 | 129 | 0.180 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2017 | 19 | 0.170 |
Why?
|
| Prosthesis-Related Infections | 1 | 2022 | 215 | 0.170 |
Why?
|
| Hip Prosthesis | 2 | 2022 | 569 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2016 | 7 | 0.170 |
Why?
|
| Cell Line, Tumor | 7 | 2017 | 273 | 0.160 |
Why?
|
| Medically Underserved Area | 1 | 2019 | 13 | 0.160 |
Why?
|
| Dogs | 4 | 2007 | 261 | 0.160 |
Why?
|
| Medical Oncology | 1 | 2019 | 36 | 0.160 |
Why?
|
| Chemoradiotherapy | 1 | 2019 | 69 | 0.160 |
Why?
|
| Antineoplastic Agents | 3 | 2017 | 252 | 0.160 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2010 | 95 | 0.150 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 76 | 0.150 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2016 | 91 | 0.150 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 103 | 0.150 |
Why?
|
| Osteoarthritis | 1 | 2022 | 366 | 0.150 |
Why?
|
| Receptors, Somatomedin | 1 | 2017 | 4 | 0.150 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2017 | 55 | 0.150 |
Why?
|
| Imidazoles | 1 | 2017 | 72 | 0.140 |
Why?
|
| Ceramics | 1 | 2016 | 23 | 0.140 |
Why?
|
| Piperazines | 1 | 2017 | 93 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 329 | 0.140 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2016 | 10 | 0.140 |
Why?
|
| Synovectomy | 1 | 2016 | 4 | 0.130 |
Why?
|
| Chondroma | 3 | 2012 | 4 | 0.130 |
Why?
|
| Biocompatible Materials | 1 | 2016 | 105 | 0.130 |
Why?
|
| Child Development | 1 | 2016 | 71 | 0.130 |
Why?
|
| Cohort Studies | 1 | 2021 | 1952 | 0.130 |
Why?
|
| Femoral Neoplasms | 1 | 2015 | 4 | 0.130 |
Why?
|
| Supination | 1 | 2014 | 19 | 0.120 |
Why?
|
| Disease Management | 1 | 2016 | 122 | 0.120 |
Why?
|
| Radiotherapy Dosage | 1 | 2015 | 114 | 0.120 |
Why?
|
| Prosthesis Implantation | 1 | 2015 | 35 | 0.120 |
Why?
|
| Time Factors | 3 | 2022 | 1641 | 0.120 |
Why?
|
| Ossification, Heterotopic | 1 | 2015 | 41 | 0.120 |
Why?
|
| Prosthesis Design | 3 | 2022 | 494 | 0.120 |
Why?
|
| Arthroplasty | 1 | 2016 | 138 | 0.120 |
Why?
|
| Lung | 1 | 2015 | 158 | 0.120 |
Why?
|
| Hand Strength | 1 | 2014 | 60 | 0.120 |
Why?
|
| Wrist Joint | 1 | 2014 | 61 | 0.120 |
Why?
|
| Drug Implants | 2 | 2005 | 12 | 0.120 |
Why?
|
| Cartilage, Articular | 2 | 2016 | 534 | 0.120 |
Why?
|
| Protein Kinases | 1 | 2014 | 15 | 0.120 |
Why?
|
| Risk Factors | 2 | 2022 | 2465 | 0.120 |
Why?
|
| Telomerase | 2 | 2004 | 10 | 0.110 |
Why?
|
| Receptors, Notch | 1 | 2013 | 2 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2011 | 1247 | 0.110 |
Why?
|
| Spinal Fusion | 1 | 2020 | 518 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2014 | 107 | 0.110 |
Why?
|
| Wnt Proteins | 1 | 2013 | 16 | 0.110 |
Why?
|
| Recovery of Function | 2 | 2012 | 291 | 0.110 |
Why?
|
| Bone Matrix | 2 | 2003 | 28 | 0.100 |
Why?
|
| Fibrous Dysplasia of Bone | 1 | 2012 | 4 | 0.100 |
Why?
|
| Injections, Intralesional | 1 | 2012 | 29 | 0.100 |
Why?
|
| beta Catenin | 1 | 2013 | 49 | 0.100 |
Why?
|
| Bone Regeneration | 2 | 2003 | 75 | 0.100 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2022 | 21 | 0.100 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2022 | 39 | 0.100 |
Why?
|
| Diagnosis, Differential | 2 | 2011 | 398 | 0.100 |
Why?
|
| Range of Motion, Articular | 1 | 2014 | 707 | 0.100 |
Why?
|
| Ankle | 1 | 2011 | 17 | 0.100 |
Why?
|
| Thoracoscopy | 1 | 2010 | 16 | 0.090 |
Why?
|
| Ilium | 1 | 2010 | 31 | 0.090 |
Why?
|
| Animals | 5 | 2007 | 4634 | 0.090 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 346 | 0.090 |
Why?
|
| Age Factors | 2 | 2019 | 853 | 0.090 |
Why?
|
| Predictive Value of Tests | 1 | 2011 | 532 | 0.080 |
Why?
|
| Chicago | 1 | 2012 | 867 | 0.080 |
Why?
|
| Survival Analysis | 1 | 2008 | 310 | 0.070 |
Why?
|
| Compressive Strength | 1 | 2007 | 29 | 0.070 |
Why?
|
| Elasticity | 1 | 2007 | 40 | 0.070 |
Why?
|
| Illinois | 1 | 2008 | 241 | 0.070 |
Why?
|
| Cell Division | 3 | 2022 | 112 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2023 | 1823 | 0.070 |
Why?
|
| Muscle Proteins | 1 | 2006 | 30 | 0.070 |
Why?
|
| Radiation Tolerance | 1 | 2006 | 7 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2006 | 21 | 0.070 |
Why?
|
| Glycoproteins | 1 | 2006 | 57 | 0.070 |
Why?
|
| Transcription, Genetic | 1 | 2006 | 108 | 0.070 |
Why?
|
| Proteins | 1 | 2006 | 71 | 0.070 |
Why?
|
| Carrier Proteins | 1 | 2006 | 99 | 0.070 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 2 | 2017 | 15 | 0.070 |
Why?
|
| Phosphorylation | 2 | 2016 | 159 | 0.060 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 332 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 78 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 456 | 0.060 |
Why?
|
| Blastomycosis | 1 | 2004 | 16 | 0.060 |
Why?
|
| Arthroscopy | 1 | 2011 | 817 | 0.060 |
Why?
|
| Lower Extremity | 1 | 2023 | 38 | 0.060 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 102 | 0.060 |
Why?
|
| Surgical Flaps | 1 | 2023 | 50 | 0.060 |
Why?
|
| Bone Demineralization Technique | 1 | 2003 | 3 | 0.060 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 14 | 0.060 |
Why?
|
| Lymphocyte Count | 1 | 2023 | 35 | 0.060 |
Why?
|
| Blood Loss, Surgical | 1 | 2023 | 66 | 0.060 |
Why?
|
| Mutation | 2 | 2021 | 396 | 0.050 |
Why?
|
| Exoribonucleases | 1 | 2002 | 1 | 0.050 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2002 | 13 | 0.050 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2002 | 10 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2023 | 135 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2023 | 110 | 0.050 |
Why?
|
| Necrosis | 1 | 2022 | 27 | 0.050 |
Why?
|
| Bone Resorption | 1 | 2003 | 95 | 0.050 |
Why?
|
| Replantation | 1 | 2022 | 7 | 0.050 |
Why?
|
| Transplantation Immunology | 1 | 2002 | 4 | 0.050 |
Why?
|
| Drug Delivery Systems | 1 | 2002 | 39 | 0.050 |
Why?
|
| Printing, Three-Dimensional | 1 | 2021 | 5 | 0.050 |
Why?
|
| Signal Transduction | 2 | 2016 | 492 | 0.050 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2002 | 19 | 0.050 |
Why?
|
| Forecasting | 1 | 2002 | 117 | 0.050 |
Why?
|
| Time-to-Treatment | 1 | 2022 | 33 | 0.050 |
Why?
|
| Radiopharmaceuticals | 1 | 2022 | 53 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 38 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2022 | 91 | 0.050 |
Why?
|
| Neoplasm Grading | 1 | 2021 | 53 | 0.050 |
Why?
|
| SEER Program | 1 | 2021 | 38 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2004 | 683 | 0.050 |
Why?
|
| Cartilage | 1 | 2002 | 154 | 0.050 |
Why?
|
| DNA Damage | 2 | 2014 | 30 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2002 | 508 | 0.040 |
Why?
|
| Tendons | 1 | 2002 | 223 | 0.040 |
Why?
|
| Biomechanical Phenomena | 1 | 2002 | 680 | 0.040 |
Why?
|
| Mesna | 1 | 2019 | 3 | 0.040 |
Why?
|
| Enzyme Activation | 2 | 2014 | 112 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 3 | 2004 | 149 | 0.040 |
Why?
|
| Ifosfamide | 1 | 2019 | 14 | 0.040 |
Why?
|
| Organ Sparing Treatments | 1 | 2019 | 7 | 0.040 |
Why?
|
| Leg | 1 | 2019 | 49 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2019 | 70 | 0.040 |
Why?
|
| Arm | 1 | 2019 | 78 | 0.040 |
Why?
|
| Pyrazines | 1 | 2017 | 11 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2017 | 66 | 0.040 |
Why?
|
| Receptor Cross-Talk | 1 | 2016 | 7 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 177 | 0.030 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2014 | 5 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2014 | 6 | 0.030 |
Why?
|
| RNA Interference | 1 | 2014 | 34 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 42 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 65 | 0.030 |
Why?
|
| Hedgehog Proteins | 1 | 2013 | 10 | 0.030 |
Why?
|
| Culture Techniques | 1 | 1992 | 24 | 0.030 |
Why?
|
| Extracellular Matrix Proteins | 1 | 1992 | 131 | 0.020 |
Why?
|
| Proteoglycans | 1 | 1992 | 345 | 0.020 |
Why?
|
| Acridine Orange | 1 | 2006 | 1 | 0.020 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2006 | 10 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 57 | 0.020 |
Why?
|
| Gamma Rays | 1 | 2006 | 16 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2006 | 113 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2006 | 78 | 0.020 |
Why?
|
| Cell Survival | 1 | 2006 | 165 | 0.020 |
Why?
|
| Manubrium | 1 | 2004 | 2 | 0.010 |
Why?
|
| Sternoclavicular Joint | 1 | 2004 | 6 | 0.010 |
Why?
|
| Chondrocytes | 1 | 2004 | 203 | 0.010 |
Why?
|
| Models, Animal | 1 | 2003 | 128 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2004 | 198 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2002 | 27 | 0.010 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 2002 | 6 | 0.010 |
Why?
|
| Telomere | 1 | 2002 | 7 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2002 | 57 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 263 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 131 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2002 | 323 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2003 | 744 | 0.010 |
Why?
|
| Sepharose | 1 | 1992 | 5 | 0.010 |
Why?
|
| Glucuronic Acid | 1 | 1992 | 9 | 0.010 |
Why?
|
| Hexuronic Acids | 1 | 1992 | 10 | 0.010 |
Why?
|
| Alginates | 1 | 1992 | 10 | 0.010 |
Why?
|
| Gels | 1 | 1992 | 11 | 0.010 |
Why?
|
| Keratan Sulfate | 1 | 1992 | 27 | 0.010 |
Why?
|
| Microspheres | 1 | 1992 | 31 | 0.010 |
Why?
|
| Lectins, C-Type | 1 | 1992 | 112 | 0.010 |
Why?
|
| Extracellular Matrix | 1 | 1992 | 75 | 0.010 |
Why?
|
| Cattle | 1 | 1992 | 218 | 0.010 |
Why?
|
| Aggrecans | 1 | 1992 | 155 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1992 | 682 | 0.010 |
Why?
|